ES8504254A1 - Procedimiento para obtener un polipeptido - Google Patents

Procedimiento para obtener un polipeptido

Info

Publication number
ES8504254A1
ES8504254A1 ES524245A ES524245A ES8504254A1 ES 8504254 A1 ES8504254 A1 ES 8504254A1 ES 524245 A ES524245 A ES 524245A ES 524245 A ES524245 A ES 524245A ES 8504254 A1 ES8504254 A1 ES 8504254A1
Authority
ES
Spain
Prior art keywords
hsv
herpes simplex
production
viral proteins
simplex viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES524245A
Other languages
English (en)
Other versions
ES524245A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MGI Pharma Inc
Original Assignee
Molecular Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8504254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/400,028 external-priority patent/US4818694A/en
Priority claimed from US06/510,551 external-priority patent/US4891315A/en
Application filed by Molecular Genetics Inc filed Critical Molecular Genetics Inc
Publication of ES8504254A1 publication Critical patent/ES8504254A1/es
Publication of ES524245A0 publication Critical patent/ES524245A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER UN POLIPEPTIDO.COMPRENDE: A) CULTIVAR UN ORGANISMO UNICELULAR QUE CONTIENE UN VECTOR RECOMBINANTE, QUE ABARCA UNA SECUENCIA DE ADN, QUE CODIFICA UN POLIPEPTIDO CON UN DETERMINANTE INMUNORREACTIVO Y ANTIGENO DE UNA GLICOPROTEINA DE VIRUS DE HERPEX SIMPLEX Y ES CAPAZ DE REPLICARSE, TRANSCRIBIRSE Y TRADUCIRSE EN UN ORGANISMO CELULAR; Y B) AISLAR AL POLIPEPTIDO DEL CULTIVO. EL ORGANISMO CELULAR ES UN ORGANISMO PROCARIOTICO COMO ESCHERICHIA COLI, EL VECTOR RECOMBINANTE PUEDE SER PEH51 O UN MUTANTE DEL MISMO, REPLICON PBR322, PEH4-2 Y PEH82 Y OTROS.SE UTILIZA PARA EL CONTROL Y LA TERAPIA DE LAS INFECCIONES VIRICAS.
ES524245A 1982-07-20 1983-07-19 Procedimiento para obtener un polipeptido Granted ES524245A0 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/400,028 US4818694A (en) 1982-07-20 1982-07-20 Production of herpes simplex viral protein
US43636882A 1982-10-25 1982-10-25
US06/510,551 US4891315A (en) 1982-10-25 1983-07-06 Production of herpes simplex viral porteins

Publications (2)

Publication Number Publication Date
ES8504254A1 true ES8504254A1 (es) 1985-04-01
ES524245A0 ES524245A0 (es) 1985-04-01

Family

ID=27410368

Family Applications (2)

Application Number Title Priority Date Filing Date
ES524245A Granted ES524245A0 (es) 1982-07-20 1983-07-19 Procedimiento para obtener un polipeptido
ES529225A Granted ES529225A0 (es) 1982-07-20 1984-01-27 Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES529225A Granted ES529225A0 (es) 1982-07-20 1984-01-27 Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.

Country Status (14)

Country Link
EP (1) EP0101655B1 (es)
CA (1) CA1295561C (es)
DE (1) DE3382072D1 (es)
DK (1) DK333183A (es)
ES (2) ES524245A0 (es)
FI (1) FI83974C (es)
GR (1) GR78647B (es)
IE (1) IE56902B1 (es)
IL (1) IL69269A (es)
NO (1) NO172855C (es)
NZ (1) NZ204948A (es)
PH (1) PH21239A (es)
PL (1) PL150654B1 (es)
PT (1) PT77014B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
EP0133063B1 (en) * 1983-06-23 1987-01-07 Stanley Dr. Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
DE3582200D1 (de) * 1984-07-20 1991-04-25 Chemo Sero Therapeut Res Inst Rekombinante dns, enthaltend ein herpes-simplex-virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex-virus-proteinen.
US4659568A (en) * 1985-02-27 1987-04-21 American Cyanamid Company Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
DE3510734A1 (de) * 1985-03-25 1986-09-25 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines fuer herpes simplex virus typ 2 spezifischen antigens, dazu geeignetes mittel und verwendung dieses antigens
JPH0668B2 (ja) * 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens

Also Published As

Publication number Publication date
PT77014B (en) 1986-01-24
IE831690L (en) 1984-01-20
IL69269A0 (en) 1983-11-30
GR78647B (es) 1984-09-27
NO172855C (no) 1993-09-15
EP0101655B1 (en) 1991-01-02
EP0101655A3 (en) 1985-12-18
IE56902B1 (en) 1992-01-29
CA1295561C (en) 1992-02-11
DE3382072D1 (de) 1991-02-07
ES8505253A1 (es) 1985-05-16
ES524245A0 (es) 1985-04-01
NO832626L (no) 1984-01-23
PL150654B1 (en) 1990-06-30
PT77014A (en) 1983-08-01
EP0101655A2 (en) 1984-02-29
FI832632A0 (fi) 1983-07-19
FI83974C (fi) 1991-09-25
IL69269A (en) 1989-12-15
DK333183D0 (da) 1983-07-19
FI832632L (fi) 1984-01-21
PH21239A (en) 1987-08-21
NZ204948A (en) 1987-10-30
FI83974B (fi) 1991-06-14
ES529225A0 (es) 1985-05-16
PL243134A1 (en) 1984-08-13
NO172855B (no) 1993-06-07
DK333183A (da) 1984-01-21

Similar Documents

Publication Publication Date Title
ES8505253A1 (es) Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.
Knipe et al. Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion
GR3024144T3 (en) Recombinant herpes simplex viruses vaccines and methods
ATE93894T1 (de) Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.
DK163187C (da) Fremgangsmaader til fremstilling af humant immuninterferon (gamma-interferon) samt dna-fragmenter, rekombinante klonings- og udtrykkelsesvektorer og rekombinante mikroorganismer og cellekulturer til anvendelse herved
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
NO2003010I2 (no) Pegfilgrastim
EP0217919A4 (en) TYPE-SPECIFIC PAPILLOMAVIRUS DNA SEQUENCES AND PEPTIDES.
ES8500324A1 (es) Procedimiento para la obtencion de proteina heterologa.
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
DK361483A (da) Gaerhybridvektorer samt deres anvendelse ved fremstilling af polypeptider
GR80840B (en) Novel polypeptide with a - amylase inhibiting effect, method for the preparation thereof, use and pharmaceutical preparations thereof
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
EP0192988A3 (en) Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
GR3007031T3 (es)
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
NZ242641A (en) Herpesvirus particles lacking a capsid and viral dna and viral preparations containing them
GR3006212T3 (es)
Leung et al. A direct cloning-expression system for neutralization antigens of herpes simplex viruses.
JPS6485092A (en) Production of protein
TW287199B (en) A method for genetically producing a protein exhibiting the activity of epstein-barr virus DNA polymerase